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Autism spectrum disorders (ASD) are currently diagnosed in the presence of impairments
in social interaction and communication, and a restricted range of activities and interests.
However, there is considerable variability in the behaviors of different individuals with an
ASD diagnosis. The heterogeneity spans the entire range of IQ and language abilities, as
well as other behavioral, communicative, and social functions. While any psychiatric con-
dition is likely to incorporate a degree of heterogeneity, the variability in the nature and
severity of behaviors observed in ASD is thought to exceed that of other disorders. The
current paper aims to provide a model for future research into ASD subgroups. In doing so,
we examined whether two proposed risk factors – low birth weight (LBW), and in utero
exposure to selective serotonin reuptake inhibitors (SSRIs) – are associated with greater
behavioral homogeneity. Using data from the Western Australian Autism Biological Reg-
istry, this study found that LBW and maternal SSRI use during pregnancy were associated
with greater sleep disturbances and a greater number of gastrointestinal complaints in
children with ASD, respectively. The findings from this “proof of principle” paper provide
support for this “bottom-up” approach as a feasible method for creating homogenous
groups.
Keywords: autism spectrum disorders, heterogeneity, autism phenotype
INTRODUCTION
Autism spectrum disorders (ASD) are currently diagnosed in the
presence of impairments in social interaction and communication,
and a restricted range of activities and interests. However, there is
considerable variability in the behaviors of different individuals
with an ASD diagnosis. Traditionally, researchers have conceptu-
alized ASD as a unitary disorder with a large spectrum, and have
sought to discover a single aetiological factor that leads to disor-
der. However, the behavioral heterogeneity has been mirrored at
the genetic level, for instance, many susceptibility loci have been
identified, yet each has been found to account for a small amount
of variance only (1–2%) (Weiss et al., 2008). A proposition that
has gathered momentum over the last decade involves moving
away from the traditional conceptualization of ASD as a unitary
disorder toward conceptualizing a syndrome of multiple and sep-
arate disorders; in essence, re-examining “autism” as “the autisms”
(Geschwind and Levitt, 2007; Whitehouse and Stanley, 2013).
Research in this area has traditionally adopted a “top-down
approach” by constraining behavioral phenotypes in the hope
that this will facilitate the identification of biological subtypes.
For example, Buxbaum et al. (2001) reported linkage evidence
for a susceptibility gene for Autistic Disorder on chromosome 2.
In an analysis of 95 affected-relative pair families with Autistic
Disorder they found a maximum multipoint heterogeneity LOD
score (HLOD) of 1.96 and a maximum multipoint NPL score of
2.39 on chromosome 2q (at 186cM, for D2s364). When families
were grouped according to delayed onset (at age >36 months) of
phrase speech, linkage to chromosome 2 increased (HLOD= 2.99,
NPL= 3.32). Shao et al. (2002) found further evidence for a sus-
ceptibility gene on chromosome 2. In an analysis of 82 sibling pairs
with Autistic Disorder they found a HLOD of 0.53 at D2S116.
When the analysis was restricted to a subset of 45 families with
phrase speech delay (>36 months), linkage to chromosome 2q
increased (HLOD= 2.12). Whilst this approach has received the
most attention in aetiological research, generally speaking, it has
underperformed, with only weak evidence that stratification based
on IQ, age at first word, or verbal ability yield a more genetically
homogenous population (Geschwind and Levitt, 2007).
A“bottom-up”approach to identify biological subtypes of ASD
has not received the same level of research attention. This method-
ology focuses on known aetiological risk factors, and whether
individuals exposed to these risk factors have a more homogenous
phenotype. In this paper, we report on this bottom-up approach,
focusing on aspects of the phenotype that are not part of the core
defining features of the disorder. We know that comorbid med-
ical conditions are highly prevalent in ASD (Bauman, 2010). Sleep
problems are thought to affect 40–80% of children on the spec-
trum (Richdale, 1999) and estimates of gastrointestinal disorders
in ASD range from 9 to 70% (Buie et al., 2010). The high preva-
lence of these comorbid conditions in children with ASD may
suggest the presence of important genetic and/or biological mark-
ers, which if identified, can refine our ability to be more precise in
categorizing clinical and genetic subtypes within the autism spec-
trum (Bauman, 2010). In this paper, we have adopted a bottom-up
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approach by stratifying groups based on two previously identified
risk factors, namely, maternal use of selective serotonin reuptake
inhibitors (SSRIs) during pregnancy and low birth weight (LBW).
The second part of our strategy involved examining the homo-
geneity within the groups based on medical complaints such as
sleep problems and gastrointestinal complaints in addition to core
features of ASD such as social behavior, language characteristics,
and severity.
Selective serotonin reuptake inhibitors use during pregnancy
has gained considerable attention over the last 2 years and is
thought to be implicated in an increased risk of ASD diagnosis
(Croen et al., 2011). Prevalence studies in the US estimate that
up to 8% of mothers may be treated with SSRIs during preg-
nancy for conditions such as anxiety disorders or major depression
(Alwan et al., 2011). SSRIs act primarily by blocking the serotonin
transporter, thereby raising extracellular serotonin (5-HT) levels
(Oberlander et al., 2009). These SSRIs readily cross the placental
and blood-brain barriers to the fetus, with the potential to alter
central 5-HT signaling (Oberlander et al., 2009). The neuroactive
properties of SSRIs are thought to be a potential risk to fetal neu-
rodevelopment, since 5-HT plays such a critical role in regulating
diverse processes such as cell division, differentiation, migration,
myelination, synaptogenesis, and dendritic pruning (Gaspar et al.,
2003). A number of researchers have hypothesized that the increase
in ASD diagnoses in recent years may be associated with a com-
mensurate increase in maternal use of antidepressant medication
during pregnancy (Croen et al., 2011). A recent population-based
case-control study by Croen et al. (2011) reviewed record-based
data describing the postnatal development of children exposed to
SSRIs in utero. This study examined data for children born through
a medical care program during the period of 1995–1999. Infants
in the sample who were later diagnosed with ASD were considered
cases. Children without an ASD diagnosis were randomly sampled
from the remaining cohort at a ratio of five control children per
one case child. Using this matched sample, Croen et al. (2011)
investigated SSRI use throughout pregnancy and found that 70
women who took antidepressant medication the year before the
birth of their child had twice the risk of having a child with ASD
(n= 20 offspring with ASD, 28.57%) compared with 1735 women
who did not take any antidepressant medication (n= 278 offspring
with ASD, 16.02%).
Using a similar population-based nested case-control design,
Rai et al. (2013) investigated the extent to which parental depres-
sion and maternal antidepressant use during pregnancy were
associated with ASDs in offspring. For parental depression, record-
based data was available for 4429 cases of ASD and 43277 age- and
sex-matched controls, and for maternal antidepressant use, data
existed for 1679 ASD cases and 16845 non-ASD controls. They
found that a history of maternal but not paternal depression was
associated with higher risk of autism in offspring. These associ-
ations were largely limited to children of mothers who reported
using antidepressants at the first antenatal interview. Antidepres-
sant use during pregnancy was reported by 1.3% of mothers of
children with ASD and by 0.6% of control mothers, equating to
an almost twofold increase in risk of ASD with use of antide-
pressants (Rai et al., 2013). Other studies that have examined the
effect of maternal SSRI use during pregnancy have observed several
atypical behavioral outcomes among offspring, including delay in
meeting gross motor milestones (Pedersen et al., 2010), a wide
range of feeding difficulties (Oberlander et al., 2006) and sleep
disturbances (Zeskind and Stephens, 2004).
Low birth weight (<2500 g) has also been considered an envi-
ronmental risk factor implicated in a range of psychiatric disorders
including ASD, anxiety disorder, and depression (Indredavik et al.,
2004; Gardener et al., 2011; Jaspers et al., 2012). Lampi et al.
(2012) examined data from the case-control Finnish Prenatal
Study of Autism and ASDs and found that children with very
LBW (<1500 g) had a greater than threefold increased odds of
autism compared with children with normal birth weight (NBW)
(2500–3999 g). Interestingly, LBW did not significantly increase
the odds of Asperger syndrome (Lampi et al., 2012). In addition
to these associated psychiatric disorders, when compared to chil-
dren with NBW, children with LBW have been found to show
pervasive motor impairments, increased socio-emotional issues,
increased risk of sleep-disordered breathing, and reductions in
language ability (Paavonen et al., 2007; de Kieviet et al., 2009;
Spittle et al., 2009; Barre et al., 2011; Scott et al., 2012). Despite
evidence supporting the role of these environmental risk factors
in the development of ASD, no single factor has been identified
that poses a determinant risk for this disorder.
This paper will adopt a “bottom-up” approach to parsing ASD
heterogeneity by investigating the behavioral phenotype associ-
ated with two possible environmental risk factors. The first study
compared the behavioral and developmental phenotype of chil-
dren with ASD whose mothers used SSRIs during pregnancy with
the phenotype for a tightly matched group of children with ASD
whose mothers did not use SSRIs during pregnancy. It was hypoth-
esized that those children with ASD whose mothers used SSRIs
during pregnancy would display early feeding and sleep distur-
bances compared to the control group of children with ASD.
We also examined whether these children showed a distinguish-
able behavioral phenotype. Study 2 compared the phenotype of
children with ASD born with LBW with a matched group of chil-
dren with ASD born with NBW. It was hypothesized that those
LBW children with ASD would display greater sleep disturbances
(e.g., sleep-disordered breathing), language difficulties, and socio-
emotional problems compared to the NBW group. This “proof of
principle” study seeks to examine two potential risk factors within
the context of a “bottom-up” research design. If the hypotheses
are supported this paper may provide a blueprint for using the
“bottom-up” approach as a feasible method for creating homoge-
nous groups compared with the more costly “top-down” approach
which requires large sample sizes.
STUDY 1
MATERIALS AND METHODS
Participants
Participants were part of the Western Australian Autism Biological
Registry (WAABR), which is an ongoing study of children with a
clinical diagnosis of an ASD and their families taking place at the
Telethon Institute for Child Health Research in Perth,Western Aus-
tralia (see Taylor et al., in press). Diagnosing ASD in Western Aus-
tralia mandates assessment by a clinical team comprising a Pedi-
atrician, Psychologist, and Speech-Language Pathologist under
Frontiers in Human Neuroscience www.frontiersin.org September 2013 | Volume 7 | Article 606 | 2
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Unwin et al. Heterogeneity in ASD
DSM-IV guidelines (American Psychiatric Association, 1994). A
diagnosis is only made when there is consensus amongst the team.
The current study included nine participants from the WAABR
whose mothers reported SSRI use during pregnancy (cases). Each
of these participants was individually matched on gender and
chronological age at assessment (within 15 months) with three
further children with ASD (n= 27) whose mothers did not take
an SSRI during pregnancy.
Measures and procedure
Prior to attending a face-to-face assessment, families were mailed
and asked to complete a comprehensive case-history questionnaire
relating to the mother’s pregnancy and the ASD child’s devel-
opment. Mothers were asked to provide details of any history
of psychological disorder such as major depression or anxiety.
They were also asked to provide the name of any prescription
or non-prescription medications, the dosage, and the amount
they used during pregnancy. A series of questionnaires were also
included in this package, including the Social Responsiveness Scale
(SRS; Constantino and Gruber, 2002), Children’s Sleep Habits
Questionnaire (CSHQ; Owens et al., 2000), Children’s Communi-
cation Checklist-2 (CCC-2; Bishop, 2003), and a gastrointestinal
complaints questionnaire (Ibrahim et al., 2009).
The SRS is a 65-item questionnaire used to examine a range
of social behaviors characteristic of ASD in children over the last
6 months. A total score can be calculated for the SRS as well as
five subscale scores, namely, social communication, autism man-
nerisms, social motivation, social awareness, and social cognition.
Parents respond using a four-point scale ranging from “not true”
(1) to“almost always true”(4). A higher total score on this measure
is indicative of greater social difficulties. The CSHQ is a 34-item
parent-report instrument that was used to examine sleep behav-
ior over a “typical week.” Parents were asked to rate how often
their child showed behaviors such as “struggle at bedtime” and
“show fear at sleeping alone” using a one to three point scale cor-
responding to “rarely,” “sometimes,” or “usually,” respectively. A
total score and eight subscale scores (bedtime resistance, sleep
onset delay, sleep duration, sleep anxiety, night wakings, para-
somnias, sleep-disordered breathing, and daytime sleepiness) can
be calculated for responses on the CSHQ. Higher total scores on
the CSHQ indicate that the child has a greater number of sleep
problems.
The CCC-2 is a parent-report questionnaire designed to assess
the communication skills of children aged 4–16 years. The pur-
poses of the CCC-2 are the identification of pragmatic language
impairment, screening of receptive and expressive language skills,
and assistance in screening for ASD. The CCC-2 consists of 70
items that are divided into 10 scales, each with 7 items. The first
four scales focus on specific aspects of language and communi-
cations skills (content and form). The next four scales assess the
pragmatic aspects of communication. The last two scales mea-
sure behaviors that are usually impaired in children with ASDs.
The parent rates the frequency of the communication behavior
described in each item from 0 (less than once a week or never)
to 3 (several times a day or always). Interpretation is based on
a General Communication Composite (GCC), with lower scores
indicative of greater language and communication difficulties.
Parents also completed a brief questionnaire related to their
child’s history of gastrointestinal problems. This questionnaire was
developed specifically for the WAABR case-history questionnaire
based on the list of complaints in Ibrahim et al. (2009). After
reviewing the literature related to gastrointestinal symptoms they
identified five categories that have been reported to be common
in patients with autism, namely, constipation, diarrhea, gastro-
esophageal reflux or vomiting, abdominal discomfort/irritability,
or feeding issues (Ibrahim et al., 2009). If the parent reported
their child had experienced any of the five gastrointestinal com-
plaints for a period of at least a month, resulting in consultation
with their doctor, they received a score of one for the indicated
complaint(s). Any other reports received a score of zero. Using
this scoring method these complaints were analyzed in two ways:
(1) individually to see if the frequency of each complaint dif-
fered between the two groups and (2) as a summary measure
of gastrointestinal complaints (score of one or more) versus no
gastrointestinal complaints (score of zero).
Families were then invited to the Telethon Institute for Child
Health Research for a face-to-face behavioral assessment. Clinical
diagnoses of ASD were confirmed using the Autism Diagnostic
Observation Schedule-Generic (ADOS-G; Lord et al., 2000). The
present study used the child’s age and ADOS module (reflective of
their quantity of speech) to calibrate severity scores (0–10) for each
participant according to the severity scale of Gotham et al. (2009).
This enabled comparisons between the participants, irrespective
of the module they completed.
Statistical analyses
Between-group differences in the quantitative scores of the SRS,
CCC-2, CSHQ, and ADOS severity scale were investigated with
independent-samples t -tests. Responses to the gastrointestinal
complaints questionnaire were analyzed according to whether par-
ents reported zero complaints or one or more complaints for
their children using chi-square analyses with Fisher’s exact test
of significance.
RESULTS
The SSRI case (n= 9) and control (n= 27) groups did not sig-
nificantly differ on gestational age [F(1, 34)= 1.05, p> 0.05] or
maternal age at conception [F(1, 34)= 3.45, p> 0.05]. Table 1
provides details of the maternal, pregnancy and offspring charac-
teristics of the case group.
Independent-samples t -tests revealed that there were no sig-
nificant differences between the two groups on any of the SRS,
CCC-2, CSHQ, or ADOS severity scores (Table 2). However,
analysis of responses to the gastrointestinal complaints ques-
tionnaire found that mothers who used SSRIs during pregnancy
were more likely to have a child with ASD who experienced one
or more gut problems (n= 8, 88.9%), compared to the control
group (n= 13, 48.1%), χ2(1), p= 0.05. To further investigate
this association, chi-square analyses with Fisher’s exact test were
performed on the five individual complaints (Table 3). The indi-
vidual complaints did not significantly differentiate between the
groups. However, the percentage of constipation complaints was
noticeably larger (though, not significantly) for cases compared to
controls.
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Table 1 | Study 1: maternal and offspring characteristics of the SSRI case group.
Maternal Offspring
SSRI taken
during
pregnancy
Period of
pregnancy
SSRI taken
Psychiatric
diagnosis
Gestational
age at birth
(weeks)
Age at
assessment
ADOS
module
administered
ADOS
severity
score
CSHQ
score
SRS
score
Number of
gut
problems
Case 1 Lexapro Daily Major depression 41 5, 6 2 1 42 146 2
Case 2 Lexapro Daily Major depression 40 4, 6 2 6 62 157 1
Case 3 Lovan 3 months Major depression 36 5, 2 2 8 54 158 4
Case 4 Effexor Daily Major depression 38 10, 2 3 3 46 172 2
Case 5 Not specified – Major depression 38 4, 3 2 7 59 166 0
Case 6 Escitalopram Daily – 38 2, 9 1 4 77 207 1
Case 7 Fluoxetine Daily Anxiety disorder 40 8, 5 3 3 63 145 1
Case 8 Aropax 1 month Anxiety disorder 39 3, 1 1 6 54 120 2
Case 9 Zoloft Daily Depression 38 3, 5 1 6 41 90 1
Table 2 | Study 1: descriptive statistics and independent-samples
t -tests for CSHQ, SRS, and ADOS severity scores.
SSRI cases Controls Statistic p
M SD M SD
CSHQ 55.56 11.36 51.58 11.96 t (31)=
0.86
0.40
Bedtime resistance 9.56 2.79 9.83 3.25
Sleep onset delay 1.89 0.60 1.83 0.87
Sleep duration 5.11 2.42 4.96 2.39
Sleep anxiety 4.89 1.45 4.79 1.82
Night wakings 6.00 1.50 5.04 2.03
Parasomnias 11.33 2.78 9.58 3.36
Sleep dis-breathing 4.11 1.83 4.08 1.56
Daytime sleepiness 12.67 3.16 11.46 2.95
SRS 151.22 32.84 145.11 25.86 t (34)=
0.57
0.57
Social awareness 16.56 1.81 16.44 2.94
Social cognition 28.78 8.23 26.56 6.24
Social communication 50.33 12.58 47.74 8.88
Social motivation 25.56 5.36 24.93 5.95
Autistic mannerisms 30.00 7.78 29.44 7.54
ADOS severity 4.89 2.26 5.93 1.96 t (34)=
1.32
0.19
CCC-2
GCC 30.75 6.99 36.15 16.53 t (15)=
0.63
0.54
DISCUSSION
This is the first study to examine the relationship between
SSRI exposure and ASD phenotype. There were no differences
between the cases and individually matched control partici-
pants in scores on the SRS, CCC-2, CSHQ, or ADOS-G sever-
ity. However, children with ASD whose mothers took SSRIs
during pregnancy were significantly more likely to experience
gastrointestinal complaints during childhood. Further examina-
tion of the relationship between gastrointestinal complaints and
in utero SSRI exposure revealed that no individual complaint
could significantly differentiate the two groups. While this does
Table 3 | Study 1: chi-square analyses using Fisher’s exact test for
both groups of children for the five gastrointestinal complaints.
Gut complaint SSRI cases N (%) Control N (%) p
Constipation 4 (44.4) 4 (14.8) 0.09
Diarrhea 2 (22.2) 3 (11.1) 0.58
Gastro reflux 2 (22.2) 3 (11.1) 0.58
Abdominal 1 (11.1) 2 (7.4) 1.00
Feeding 5 (55.6) 8 (29.6) 0.24
One or more complaints 8 (88.9) 13 (48.1) 0.05
not support Oberlander et al. (2009) who found evidence for
feeding disturbances in typically developing infants exposed to
SSRIs in utero, it is possible that the small sample size con-
tributed to the null findings for the less-frequent individual
complaints.
The current study was limited by the absence of a control group
of children whose mothers had affective disorders but who did
not take SSRIs during pregnancy, and therefore we are unable to
parse out whether the differences in the frequency of gut prob-
lems is related to mood disturbances or SSRI use. Rai et al.
(2013) reported an association between maternal depression and
an increased risk of offspring ASD. Although they found that this
association was largely confined to antidepressant use in a sub-
sample of mothers, future studies could build on the findings
presented here and in Rai et al. (2013) by comparing the phe-
notype for children with ASD whose mothers report untreated
depression during pregnancy with a matched ASD control group
of children. The hypothesized association between ASD and gas-
trointestinal pathology is the subject of increasing amounts of
research. Despite the numerous parental reports of gastrointesti-
nal complaints among their children with ASD, studies have failed
to find a significant difference in the prevalence of these com-
plaints between children with ASD and control groups of children
(e.g., Ibrahim et al., 2009). The current findings suggest that
SSRI exposure in utero may be one potential candidate account-
ing for variance in the gut phenotype in children diagnosed
with ASD.
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STUDY 2
MATERIALS AND METHODS
Participants
The study involved using data for 16 participants from WAABR
whose birth weight was ≤2500 g (LBW). Each of these partici-
pants was individually matched on gender and chronological age
at assessment (within 18 months) with two further control chil-
dren with ASD (n= 32) whose birth weight was within the normal
range (NBW; 2500–3999 g).
Measures and procedure
Within the case-history questionnaire, mothers were asked to
report their child’s birth weight. For the purposes of Study 2,
data collected for each child using the SRS, CSHQ, ADOS sever-
ity, CCC-2, and gastrointestinal complaints questionnaire were
analyzed.
Statistical analyses
Between-group differences in the quantitative scores of the SRS,
the CSHQ, CCC-2, and ADOS severity scale were investigated with
independent-samples t -tests. Responses to the gastrointestinal
complaints questionnaire were analyzed using chi-square analyses
with Fisher’s exact test of significance.
RESULTS
The LBW (n= 16) and the NBW (n= 32) groups did not sig-
nificantly differ on maternal age at conception [F(1, 45)= 0.07,
p> 0.05]. Mean gestational age was significantly lower for
the LBW group [F(1, 43)= 28.53, p< 0.05, M= 34.25 weeks,
SD= 4.55 weeks] relative to the NBW group (M = 39.07 weeks,
SD= 1.33 weeks, p< 0.05). Table 4 provides details of the off-
spring characteristics of the case group. Independent-samples
t -tests (see Table 5) revealed that LBW children with ASD had sig-
nificantly higher scores relative to the NBW group on the CSHQ
for Total Sleep Disturbance and two of the subscales, namely,
Sleep-Disordered Breathing and Daytime Sleepiness. There were
no significant differences between the two groups on the SRS,
CCC-2, or ADOS severity scores (Table 5).
Similarly, children with LBW (n= 16, 81%) did not experience
significantly greater gastrointestinal issues compared to the NBW
group (n= 32, 53%), χ2(1), p= 0.07. To further investigate this
association, chi-square analyses with Fisher’s exact test were per-
formed on the five individual complaints (Table 6). The individual
complaints did not significantly differentiate between the groups.
DISCUSSION
The second study examined the phenotype of children with ASD
born with LBW relative to a group of children with ASD born with
NBW. This study did not find any significant differences between
the groups on the gastrointestinal complaints questionnaire, SRS,
ADOS-G severity, or CCC-2. This is inconsistent with findings
of greater socio-emotional issues and reduced language ability in
LBW children compared to NBW children in the absence of an
ASD diagnosis (Barre et al., 2011; Scott et al., 2012). The present
study did find that children in the LBW group obtained higher
mean scores on the CSHQ for total sleep disturbance, Daytime
Sleepiness, and Sleep-Disordered Breathing relative to the NBW
group. This supports the finding of sleep-disordered breathing in
children with LBW without an ASD diagnosis (e.g., Paavonen et al.,
2007). Interestingly, compared to norms from typically developing
children (M = 3.24) and children with ASD (M= 3.92) (Hoffman
et al., 2006), LBW children with ASD obtained larger mean scores
for the Sleep-disordered Breathing subscale (M = 4.31).
Currently, there are no norms to describe performance of
typically developing LBW children on the CSHQ. It would be
interesting to compare sleep disturbance between LBW typically
developing children and LBW children with ASD. Thus it may be
useful to conduct a more comprehensive study of LBW and NBW
children with and without ASD to look more closely at the signif-
icance of the present findings. Unsurprisingly, the LBW children
Table 4 | Study 2: offspring characteristics of the LBW case group.
Birth
weight
Gestational
age at birth
Age at
assessment
ADOS
module
ADOS severity
score
CSHQ score SRS score GCC Number of
gut problems
Case 1 600 24 11; 1 3 4 45 152 42 1
Case 2 895 27 7; 4 2 6 57 166 32 3
Case 3 985 29 5; 6 1 3 39 133 38 1
Case 4 1565 30 4; 7 1 6 42 172 – 0
Case 5 1640 37 5; 2 1 6 65 169 40 2
Case 6 1665 37 5; 2 2 4 56 143 49 1
Case 7 1725 35 14; 4 3 4 63 171 28 3
Case 8 1765 34 2; 8 1 7 47 107 – 1
Case 9 2097 40 13; 1 1 6 54 183 – 2
Case 10 2285 36 5; 2 2 8 54 158 – 4
Case 11 2300 37 5; 11 1 7 51 163 – 0
Case 12 2426 37 9; 7 1 8 69 200 - 1
Case 13 2450 32 4; 7 2 6 52 159 56 1
Case 14 2500 38 4; 3 2 7 59 166 39 0
Case 15 2125 37 11; 3 3 6 66 191 7 1
Case 16 2480 38 4; 6 2 5 66 156 – 2
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Table 5 | Study 2: descriptive statistics and independent-samples
t-tests for CSHQ, SRS, CCC-2, and ADOS severity score.
LBW NBW Statistics p
M SD M SD
CSHQ 55.31 9.08 47.84 8.84 t (45)=
2.72
0.01
Bedtime resistance 9.81 2.76 8.13 2.38
Sleep onset delay 1.88 0.72 1.52 0.68
Sleep duration 5.69 2.39 4.55 1.93
Sleep anxiety 4.63 1.63 4.74 1.86
Night wakings 5.19 1.87 4.19 1.66
Parasomnias 10.44 2.71 9.97 2.56
Sleep dis-breathing 4.31 1.49 3.29 0.82 t (45)=
3.04
0.00
Daytime sleepiness 13.38 3.36 11.19 2.56 t (45)=
2.48
0.02
SRS t (45)=
0.75
0.46
Social awareness 17.31 2.73 17.97 2.33
Social cognition 30.25 3.64 28.77 5.81
Social communication 54.00 8.25 51.13 8.58
Social motivation 27.69 4.70 26.68 4.88
Autistic mannerisms 32.56 7.16 31.68 7.36
ADOS severity 5.81 1.47 6.56 1.98 t (46)=
1.34
0.19
CCC-2
GCC 36.78 13.92 28.88 13.67 t (31)=
1.47
0.15
Table 6 | Study 2: chi-square analyses using Fisher’s exact test for
both groups of children for the five gastrointestinal complaints.
Gut complaint LBW N (%) NBW N (%) p
Constipation 7 (43.8) 9 (28.1) 0.22
Diarrhea 2 (12.5) 3 (9.4) 0.55
Gastro reflux 5 (31.3) 8 (25) 0.45
Abdominal 0 (0) 4 (12.5) 0.19
Feeding 9 (56.3) 13 (40.6) 0.24
One or more complaints 8 (88.9) 13 (48.1) 0.05
had a significantly lower gestational age at birth than the NBW
children, which raises the possibility that gestational age may be
driving the findings and not birth weight. However, it is impor-
tant to note that the study by Lampi et al. (2012), which informed
our hypotheses, found that LBW was a better predictor of ASD
diagnosis than was prematurity.
GENERAL DISCUSSION
This present study used a “bottom-up” approach to seek under-
standing of the heterogeneity of ASD by investigating the behav-
ioral phenotype associated with two suspected environmental risk
factors, namely, in utero SSRI exposure and LBW. It was hypoth-
esized that children with ASD who were exposed to one of these
environmental risk factors would present with a more homoge-
nous phenotype relative to individually matched control groups
of children with ASD. There was some preliminary support for
this hypothesis. While the children in the LBW and SSRI-exposed
groups were no different to their respective control groups in quan-
titative and qualitative measures of the core symptomatology of
autism, there was evidence that the two groups were distinct in
the level of their non-core symptomatology such as sleep and
gastrointestinal complaints, respectively.
The numbers of children with ASD in the “aetiological risk”
subgroups are small, and therefore we urge caution in drawing
conclusions from these data. Rather, we seek to highlight a dif-
ferent method for understanding the heterogeneity in the ASD
phenotype. We believe that the preliminary findings of increased
levels of non-core symptoms of ASD among certain “aetiological
risk” subgroups, provides evidence that this “bottom-up” method-
ology may assist ASD research. Studies including larger samples of
children with ASD will build on the research presented here, and
provide the opportunity to validate our preliminary findings.
Whilst the present study did not find any differences in core
ASD symptoms between LBW and SSRI-exposed children with
their respective control groups, we know that each child who is
given an ASD diagnosis presents with the triad of core symptoms
irrespective of their severity. It is unlikely that a single environ-
mental factor could be attributed to “causing” one of these core
impairments. Rather we may expect that the interplay between
the environment and a child’s genetic profile contributes to the
variable expression of autistic-related traits (Ratajczak, 2011).
Therefore, it seems reasonable that environmental factors may be
related to the expression of non-core ASD symptoms among these
children rather than to any variance in core symptomatology.
Recently, Whitehouse and Stanley (2013) reaffirmed an emerg-
ing view in the literature with regard to reconceptualizing autism in
moving away from a unitary disorder with one cause, and toward
an “umbrella” for a collection of behavioral disorders resulting
from a range of causal pathways. In their paper they describe
how research in cerebral palsy may be analogous to research on
autism. Initially cerebral palsy was thought to be a unitary dis-
order caused by anoxia secondary to trauma occurring during
labor and delivery. However, the heterogeneity in symptoms and
severity amongst children with cerebral palsy led researchers to
hypothesize that there may be many causal pathways. Many other
causes were identified for cerebral palsy following this reconceptu-
alization, such as complications of preterm birth, infections, and
inflammation in utero (McIntyre et al., 2012). For diagnosis, cere-
bral palsy is now considered an umbrella term covering a wide
range of syndromes that arise secondary to a number of brain
lesions/anomalies occurring early in development (Badawi et al.,
2008).
A key question facing the field is whether the long-held view
that autism is a unitary disorder with a single causal pathway is cor-
rect, or whether autism may best be conceptualized as an umbrella
term for a collection of behavioral disorders resulting from a range
of causal pathways, analogous to cerebral palsy. Current evidence
suggests that the latter may be a more accurate representation. Het-
erogeneity in the distal causes of autism is now well-established. It
is estimated that between 10 and 15% of individuals with autism
have a known genetic aetiology, but the loci and nature of these
lesions vary, from known syndromes to observable cytogenetic
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lesions and rare de novo mutations (e.g., copy number variations)
(Abrahams and Geschwind, 2008). Among those with idiopathic
autism, no single genetic risk variant has been found to occur in
more than 1% of individuals (Abrahams and Geschwind, 2008).
Similarly, environmental risk factors identified through epidemi-
ological studies and examined in this study – in utero exposure
to SSRIs (Croen et al., 2011) and LBW (Lampi et al., 2012) – dif-
fer considerably in the hypothesized biological paths to disorder,
and as yet, no known environmental exposure is deterministic of
autism.
Given that diagnosis is currently based on behavior, the ques-
tion of whether autism is one or multiple disorders is ultimately
a query over the proximal causes of these behaviors, and one
perhaps best addressed in neuroscience. Neuroscientific stud-
ies may help determine whether (a) distal risk factors “fan in”
on a common neurobiological substrate that has the capabil-
ity of underpinning the considerable behavioral heterogeneity
in autism (one disorder), or (b) the exact combination of dis-
tal risk factors determines the brain regions and functions that
are affected, which in turn prescribe the behavioral profile of
each individual (multiple disorders). A key research aim will be
to investigate the correspondence (if any) between known distal
(genetic and environmental) and proximal (neurobiological) risk
factors for autistic behaviors,using increasingly sophisticated envi-
ronmental monitoring, genetic sequencing, and neuroimaging
techniques.
Using preliminary data in this study we have demonstrated
how a “bottom-up” approach can be applied to current aeti-
ological research. Grouping individuals using this method may
facilitate the identification of subtypes of people with ASD. Elu-
cidating the underlying nature of the disorder(s) is a crucial step
toward achieving perhaps the “holy grail” of autism research: tai-
loring intervention to the biological and cognitive makeup of each
individual (Whitehouse and Stanley, 2013).
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